ABUS vs. CALT, PAHC, ALT, IGMS, SLRN, CMPS, APLT, KALV, OCS, and AVBP
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Altimmune (ALT), IGM Biosciences (IGMS), Acelyrin (SLRN), COMPASS Pathways (CMPS), Applied Therapeutics (APLT), KalVista Pharmaceuticals (KALV), Oculis (OCS), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical preparations" industry.
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
In the previous week, Calliditas Therapeutics AB (publ) had 6 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Calliditas Therapeutics AB (publ) and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.35 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the media.
Calliditas Therapeutics AB (publ) has higher revenue and earnings than Arbutus Biopharma. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Calliditas Therapeutics AB (publ) has a net margin of -38.72% compared to Calliditas Therapeutics AB (publ)'s net margin of -401.57%. Calliditas Therapeutics AB (publ)'s return on equity of -57.82% beat Arbutus Biopharma's return on equity.
Calliditas Therapeutics AB (publ) presently has a consensus price target of $34.00, indicating a potential upside of 83.78%. Arbutus Biopharma has a consensus price target of $4.33, indicating a potential upside of 57.58%. Given Arbutus Biopharma's higher possible upside, analysts plainly believe Calliditas Therapeutics AB (publ) is more favorable than Arbutus Biopharma.
Calliditas Therapeutics AB (publ) has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
Arbutus Biopharma received 398 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 70.78% of users gave Arbutus Biopharma an outperform vote while only 60.47% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 5.4% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Arbutus Biopharma beats Calliditas Therapeutics AB (publ) on 11 of the 18 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
